Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Zhang, Xiaowen; Xia, Ruyu; Gao, Jiaqi; Liu, Jinjun; Xu, De-Hao; Li, Xun; Hu, Xiao-Yang; Willcox, Merlin; Moore, Michael; Dai, Mengyuan; Trill, Jeanne; Fei, Yutong; Liu, Jianping

doi:10.3389/fphar.2022.923395

Cited by 6 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no evidence of a significant difference in adverse events between the intervention and control groups and there are no serious safety concerns ( Trill et al, 2022 ). SFJD also seems to reduce duration of symptoms in COVID-19 ( Sheng et al, 2022 ), upper respiratory tract infections ( Zhang et al, 2021 ) and in community-acquired pneumonia, when given in addition to antibiotics ( Zhang et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial

Willcox,

Hu,

Oliver

et al. 2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Background: Although many acute exacerbations of COPD (AECOPD) are triggered by non-bacterial causes, they are often treated with antibiotics. Preliminary research suggests that the Chinese herbal medicine “Shufeng Jiedu” (SFJD), may improve recovery and therefore reduce antibiotic use in patients with AECOPD.Aims: To assess the feasibility of conducting a randomised placebo-controlled clinical trial of SFJD for AECOPD in UK primary care.Methods: GPs opportunistically recruited patients experiencing an AECOPD. Participants were randomised 1:1 to usual care plus SFJD or placebo for 14 days. Participants, GPs and research nurses were blinded to treatment allocation. GPs could prescribe immediate, delayed or no antibiotics, with delayed prescribing encouraged where appropriate. Participants were asked to complete a participant diary, including EXACT-PRO and CAT™ questionnaires for up to 4 weeks. Outcomes included recruitment rate and other measures of study feasibility described using only descriptive statistics and with no formal comparisons between groups. We also conducted qualitative interviews with recruited and non-recruited COPD patients and clinicians, analysed using framework analysis.Results: Over 6 months, 19 participants (6 SFJD, 13 placebo) were recruited. Sixteen (84%) participants returned diaries or provided a diary by recall. Overall, 1.3 participants were recruited per 1,000 patients on the COPD register per month open. Median duration of treatment was 9.8 days in the intervention group vs 13.3 days in the placebo group. The main reason for discontinuation in both groups was perceived side-effects. in both groups. Point estimates for both the EXACT-PRO and CAT™ outcomes suggested possible small benefits of SFJD. Most patients and clinicians were happy to try SFJD as an alternative to antibiotics for AECOPD. Recruitment was lower than expected because of the short recruitment period, the lower incidence of AECOPD during the COVID-19 pandemic, patients starting antibiotics from “rescue packs” before seeing their GP, and workforce challenges in primary care.Conclusion: Recruitment was impaired by the COVID-19 pandemic. Nevertheless, we were able to demonstrate the feasibility of recruiting and randomising participants and identified approaches to address recruitment challenges such as including the trial medication in COPD patients’ “rescue packs” and delegating recruitment to a central trials team.Clinical Trial Registration: Identifier, ISRCTN26614726

show abstract

Section: Introductionmentioning

confidence: 99%

Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial

Willcox,

Hu,

Oliver

et al. 2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…SFJDC has the effect of clearing heat and detoxifying, dispelling wind and relieving exterior, which has been used to treat acute upper respiratory tract infection (URI) with external wind-heat syndrome.Indicative symptoms are fever, aversion to cold, sore throat, headache, nasal congestion, runny nose and cough [1][2][3]. Clinical application studies have shown that SFJDC can also treat community-acquired pneumonia, chronic obstructive pulmonary disease(COPD), and other diseases [4][5][6][7][8]. It is recommended as the treatment guideline and recommended medication for 12 major diseases, including 'TCM Diagnosis and Treatment Protocol for Wind-warm Lung-heat Disease (Viral Pneumonia) (Mild Cases)' (2017), 'Diagnosis and Treatment Protocol for exogenous fever (URI)' (2017), and is also included in the 'National Reimbursement Drug List' and 'National Essential Medicine List' .…”

Section: Introductionmentioning

confidence: 99%

Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection

Han

Zhu

et al. 2023

Chin Med

View full text Add to dashboard Cite

Shufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand traditional Chinese medicine (TCM) for the treatment of different respiratory tract infectious diseases with good clinical efficacy and few side effects. It is clinically applied to acute upper respiratory tract infection(URI), influenza, acute exacerbation of chronic obstructive pulmonary disease (AECOPD), community-acquired pneumonia(CAP) and other diseases, due to its antibacterial, antiviral, anti-inflammatory, immunoregulatory and antipyretic activities. In particular, it has shown good clinical effects for COVID-19, and was included in the fourth to tenth editions of the ‘Diagnosis and Treatment Protocol for COVID-19 (Trial)’ by the National Health Commission. In recent years, studies on the secondary development which focus on the basic and clinical application of SFJDC have been widely reported. In this paper, chemical components, pharmacodynamic material basis, mechanisms, compatibility rule and clinical application were systematically summarized, in order to provide theoretical and experimental basis for further research and clinical application of SFJDC.

show abstract

“…The Chinese herbal medicine Shufeng Jiedu® (SFJD) capsule is a patent formula consisting of eight Chinese herbs, all of which are used traditionally for treating respiratory infections (Table 1 ). SFJD is already on the market in China for treating respiratory conditions, with promising evidence showing its effects in various acute upper RTIs [ 20 ] and community-acquired pneumonia [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial

Oliver

Willcox

et al. 2022

Pilot Feasibility Stud

Self Cite

View full text Add to dashboard Cite

Background Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a major reason for consultations in primary care, hospital admissions, deterioration in function, and mortality. Despite the majority of exacerbations not being caused by bacteria, as many as 70% of patients who present in UK primary care with AECOPD are prescribed antibiotics as part of standard care. However, finding effective non-antibiotic treatments for COPD exacerbations is a priority to reduce antibiotic use. The Chinese herbal medicine Shufeng Jiedu® (SFJD) has the potential to reduce treatment failure and duration of hospital stay. This study aims to determine the feasibility of conducting a fully powered randomised, double blind, placebo-controlled clinical trial on SFJD for AECOPD in UK primary care. Methods This study is a phase III, two-arm individually double blind, randomised, placebo-controlled feasibility trial with nested qualitative study, coordinated by the Southampton Clinical Trial Unit (SCTU). Patients aged ≥ 40 years, with a current AECOPD, presenting with increased sputum purulence/volume, or breathlessness, and for whom the GP is considering use of antibiotics, will be eligible to participate. We aim to recruit seven eligible participants per month and randomise them to receive either the patent Chinese herbal medicine SFJD capsules or placebo for 14 consecutive days and to follow-up for 12 weeks. The primary outcomes include the feasibility of recruitment, study retention, and the percentage of diary completion. Discussion If this trial demonstrates the feasibility of recruitment, delivery, and follow-up, we will seek funding for a fully powered placebo-controlled trial of SFJD for the treatment of AECOPD in primary care. Trial registration This trial is registered via ISRCTN on 1 July 2021, identifier: ISRCTN26614726.

show abstract

Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Cited by 6 publications

References 45 publications

Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial

Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial

Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection

Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial

Contact Info

Product

Resources

About